Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: Implications for diabetes-associated cardiovascular disease

Diabetes

Volumn 51, Issue 4, 2002, Pages 1194-1200

  Netherton, Stuart J ^a   Jimmo, Sandra L ^a   Palmer, Daniel ^a   Tilley, Douglas G ^a   Dunkerley, Heather A ^a   Raymond, Daniel R ^a   Russell, James C ^b   Marlene Absher, P ^c   Helene Sage, E ^d   Vernon, Robert B ^d   Maurice, Donald H ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d HOPE HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENZYME ACTIVITY; GENETIC RISK; INSULIN RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

EID: 0036224605     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.4.1194     Document Type: Article

References (44)

1. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology
2. Etiology of the metabolic syndrome: Potential role of insulin resistance, leptin resistance, and other players
3. Effect of leptin in platelet and endothelial cells: Obesity and arterial thrombosis
4. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery
5. Insulin resistance and cardiovascular disease
6. Cardiovascular complications of non-insulin-dependent diabetes: The JCR:LA-cp rat
7. Cyclic AMP and mechanisms of vasodilation
8. Molecular mechanism of cGMP-mediated smooth muscle relaxation
9. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
10. Effects of prostaglandin E1, I2 and isoproterenol on the tissue cyclic AMP content in longitudinal muscle of rabbit intestine
11. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
12. Cyclic nucleotide phosphodiesterases and vascular smooth muscle
13. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)
14. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
15. Cyclic nucleotide phosphodiesterases: Relating structure and function
16. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP
17. Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle
18. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle
19. 2+ current in human atrial myocytes
20. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP
21. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: Implications for phosphodiesterase 3 inhibition in human cardiovascular tissues
22. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B
23. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B
24. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes
25. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracelludar targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
26. Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways: A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells
27. Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases: A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting
28. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase: Involvement of serine 54 in the enzyme activation
29. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: Generation of a molecular model
30. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579
31. Insulin resistance and vascular wall function: Lessons from animal models
32. Vasculopathy and insulin resistance in the JCR:LA-cp rat
33. Increased proliferation of explanted vascular smooth muscle cells: A marker presaging atherogenesis
34. Cyclic nucleotide phosphodiesterase 3 expression in vivo: Evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats
35. Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by, β β′-tetramethylhexadecanedioic acid (MEDICA16)
36. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity
37. 3H]hypoxanthine: Use in studies of cardiovascular drugs
38. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors
39. A novel, quantitative model for study of endothelial cell migration and sprout formation within three-dimensional collagen matrices
40. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr)
41. Membrane localization of cyclic nucleotide phosphodiesterase 3 PDE3: Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum
42. Functions of the N-terminal region of cyclic nueleotide phosphodiesterase 3 (PDE3) isoforms
43. Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor
44. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4: Regulation of superoxidation and mitogenesis